FDA decision by end of January?
$Zevra Therapeutics (ZVRA.US)$ The NDA filed on Dec. 22 is expected to be classified as a Class II submission, which will be subject to a six-month review. The FDA's decision to accept the NDA is expected within 30 days. Make a note to keep watch!
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more1